Entering text into the input field will update the search result below

FDA cleared Rocket Pharmaceuticals' IND for RP-L201

  • FDA clears Rocket Pharmaceuticals' (NASDAQ:RCKT) IND application for RP-L201. RP-L201 is the Company’s lentiviral vector-based gene therapy for the treatment of severe Leukocyte Adhesion Deficiency-I (LAD-I) that was in-licensed from the Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT).
  • This IND enables Rocket to initiate a Phase 1/2 clinical trial to assess the safety, tolerability, and efficacy of severe LAD-I in children.

Recommended For You

More Trending News

About RCKT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RCKT--
Rocket Pharmaceuticals, Inc.